Brokerages expect that ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) will report ($0.13) earnings per share for the current quarter, Zacks reports. Two analysts have provided estimates for ZIOPHARM Oncology’s earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.10). ZIOPHARM Oncology reported earnings per share of ($0.15) during the same quarter last year, which would indicate a positive year-over-year growth rate of 13.3%. The firm is expected to issue its next quarterly earnings results on Monday, May 7th.
On average, analysts expect that ZIOPHARM Oncology will report full-year earnings of ($0.53) per share for the current year, with EPS estimates ranging from ($0.62) to ($0.39). For the next fiscal year, analysts forecast that the company will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.74) to ($0.31). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that follow ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.59 million. The company’s revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.11) earnings per share.
Several analysts recently issued reports on the stock. BidaskClub raised shares of ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a report on Thursday, December 14th. Raymond James Financial reaffirmed a “hold” rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th. Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a report on Saturday, January 6th. Finally, ValuEngine cut shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the stock. ZIOPHARM Oncology currently has an average rating of “Hold” and a consensus price target of $7.50.
A number of hedge funds have recently added to or reduced their stakes in ZIOP. Chevy Chase Trust Holdings Inc. bought a new stake in ZIOPHARM Oncology during the third quarter valued at $104,000. G&S Capital LLC bought a new stake in ZIOPHARM Oncology during the fourth quarter valued at $125,000. Metropolitan Life Insurance Co. NY bought a new stake in ZIOPHARM Oncology during the fourth quarter valued at $139,000. Adell Harriman & Carpenter Inc. bought a new stake in ZIOPHARM Oncology during the third quarter valued at $141,000. Finally, Steward Partners Investment Advisory LLC bought a new stake in ZIOPHARM Oncology during the third quarter valued at $145,000. Hedge funds and other institutional investors own 40.19% of the company’s stock.
ZIOPHARM Oncology (NASDAQ:ZIOP) traded up $0.08 on Wednesday, reaching $4.45. 1,253,314 shares of the company traded hands, compared to its average volume of 1,417,694. The firm has a market capitalization of $622.28, a PE ratio of -8.24 and a beta of 1.42. ZIOPHARM Oncology has a 1 year low of $3.33 and a 1 year high of $7.88.
ILLEGAL ACTIVITY WARNING: “ZIOPHARM Oncology Inc. (ZIOP) Expected to Post Earnings of -$0.13 Per Share” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/ziopharm-oncology-inc-ziop-expected-to-post-earnings-of-0-13-per-share.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.